MedDataX Logo

Hypomagnesemia Associated With Proton-Pump Inhibitor Use

NCT ID: NCT04426994

Last Updated: 2020-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

211672 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Use of proton pump inhibitors has been associated with hypomagnesemia. However, various case-control or prospective studies have found conflicting results with regards to proton pump inhibitors use and development of hypomagnesemia. Our aim was to evaluate the likelihood that proton pump inhibitors contributed to severe hypomagnesemia in a retrospective cohort of patients admitted with severe hypomagenesemia. We also aimed to look for risk factors leading to development of hypomagnesemia amongst users of proton pump inhibitors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

NCT05998863

Osteoporosis Hypomagnesemia
RECRUITING PHASE3

Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors

NCT02518659

Hypomagnesemia, Intestinal, With Secondary Hypocalcemia Drug Induced Hypomagnesemia
COMPLETED NA

To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use

NCT01306799

Barrett's Esophagus Erosive Esophagitis Gastroesophageal Reflux Disease(GERD)
COMPLETED

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

NCT03812380

Osteoporosis Hypomagnesemia
TERMINATED PHASE3

Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor in Geriatric Population

NCT03467893

Proton Pump Inhibitor
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Proton Pump Inhibitor Adverse Reaction Hypomagnesemia Arrhythmias, Cardiac Seizures Hypocalcemia Hypokalemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use

proton pump inhibitor use

Intervention Type DRUG

Patients using long term proton pump inhibitor

Control

Patients on long-term proton pump inhibitor without documented hypomagnesemia

proton pump inhibitor use

Intervention Type DRUG

Patients using long term proton pump inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

proton pump inhibitor use

Patients using long term proton pump inhibitor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted with hypomagnesemia (cases)
* Patients prescribed with proton pump inhibitors (controls)

Exclusion Criteria

* Patients prescribed with less than three months duration of proton pump inhibitors (controls)
Minimum Eligible Age

14 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Changi General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Troy H Puar, MRCP

Role: PRINCIPAL_INVESTIGATOR

Changi General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Changi General Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PPI HypoMg

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test
NCT04022837 UNKNOWN PHASE2
Effect of Daily Use Proton Pump Inhibitors for One Month on Kidney Function
NCT03910647 UNKNOWN PHASE2
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
NCT01499693 WITHDRAWN PHASE3
Gastric Acid Rebound Secretion Measured by Alkaline Tide
NCT01315444 WITHDRAWN PHASE1
Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers
NCT00915239 COMPLETED NA
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
NCT01132638 COMPLETED PHASE3
Risk of Cancer Among Pantoprazole Users
NCT01322633 COMPLETED
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
NCT00206050 COMPLETED PHASE4
Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid
NCT02558049 COMPLETED NA
Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility
NCT00600041 COMPLETED PHASE1
Inappropriate Prescribing of Proton-pump Inhibitor is it Associated With the Burden of Comorbidities in Older Patients?
NCT02841852 COMPLETED
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
NCT01138969 COMPLETED PHASE2
Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis
NCT04140591 TERMINATED PHASE2/PHASE3
Effect of Proton Pump Inhibitors on Endothelial Function
NCT02022280 COMPLETED PHASE1
Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome
NCT06268834 COMPLETED NA
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
NCT01338363 COMPLETED
Effect of Obesity on Proton Pump Inhibitors
NCT04248335 COMPLETED PHASE4
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
NCT00402259 COMPLETED PHASE3
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
NCT00206024 COMPLETED PHASE4
Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children
NCT00299845 WITHDRAWN PHASE4
Acid Suppressive Therapy - Review of Appropriateness
NCT02259270 COMPLETED
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
NCT02551744 COMPLETED NA
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
NCT06054464 COMPLETED PHASE1
Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding
NCT00731601 COMPLETED PHASE4
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
NCT03908593 UNKNOWN PHASE4